

Please type a plus sign (+) inside this box ? +


PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A/PTO

Complete If Known

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(use as many sheets as necessary)



Sheet

of

4

Application Number 09/589,285

Filing Date June 8, 2000

First Named Inventor YU et al.,

Group Art Unit 1646 1647

Examiner Name Prasad, S. Bunner

Attorney Docket Number PF343P3C4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SL	A1	08/984,396		SmithKline Beecham	NA	Priority Document of EP 869180
	A2	60/033,601		Schering	NA	Priority Document of WO 98/27114
	A3	60/041,797		SmithKline Beecham	NA	Priority Document of EP 869180
	A4	60/048,776		Regeneron	NA	Priority Document of 98/55620 & 98/55621
	A5	60/058,786		Biogen	NA	Priority Document of 99/12964
	A6	60/066,386		Regeneron	NA	Priority Document of 98/55620 & 98/55621
	A7	60/066,577		Eli Lilly	NA	Priority Document of EP 921194
	A8	60/068,959		Chiron	NA	Priority Document of WO 99/33980
	A9	60/096,173		Eli Lilly	NA	Priority Document of EP 921194
	A10	60/106,976		U.S. Government - DHHS	NA	Priority Document of WO 00/26244
	A11	60/117,169		Biogen	NA	Priority Document of WO 00/43032
	A12	60/143,228		Biogen	NA	Priority Document of WO 00/43032

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SL	A13	EP 869180	A1	SmithKline Beecham	07-10-1998	—	—
	A14	EP 921194	A2	Eli Lilly	06-09-1999	—	—
	A15	EP 98302526		SmithKline Beecham	4-1998	Priority Document of EP 869180	—
	A16	EP 98309632		Eli Lilly	11-1998	Priority Document of EP 921194	—
	A17	WO 01/40466	A2	Genentech	06-07-2001	Pages 1-135 and Figures 23 and 24	—
	A18	WO 00/26244	A2	U.S. Government - DHHS	05-11-2000	—	—
	A19	WO 00/39295	A1	Glaxo	07-06-2000	—	—
	A20	WO 00/40716	A2	ZymoGenetics	07-13-2000	—	—
	A21	WO 00/43032	A2	Biogen	07-27-2000	—	—
	A22	WO 00/47740	A2	Amgen, Inc.	08-17-2000	—	—
	A23	WO 00/45836	A1	Res. Dev. Foundation	08-10-2000	—	—
	A24	WO 00/60079	A2	Chiron Corporation	10-12-2000	—	—
	A25	WO 00/67034	A1	Immunex Corporation	11-09-2000	—	—

Sarada Probed

10/30/01

Bridget E. Bunner 10/4/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(use as many sheets as necessary)</small>					
				Application Number	09/589,285
				Filing Date	June 8, 2000
				First Named Inventor	YU et al.,
				Group Art Unit	1646 1647
				Examiner Name	Prasad, S. Bunner
Sheet	of	4	Attorney Docket Number PF343P3C4		

AUG 28 2001
PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ²	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SEA	A26	WO 00/68378	A1	National Jewish Medical and Research Center	11-16-2000	—
	A27	WO 00/77256	A1	Human Genome Sciences	12-21-2000	—
	A28	WO 97/33902	A1	Human Genome Sciences	09-18-1997	—
	A29	WO 98/27114	A2	Schering	06-25-1998	—
	A30	WO 98/55620	A1	Regeneron	12-10-1998	—
	A31	WO 98/55621	A1	Regeneron	12-10-1998	—
	A32	WO 99/11791	A1	Univ. of Washington	03-11-1999	—
	A33	WO 99/12964	A2	Biogen	03-18-1999	—
	A34	WO 99/33980	A2	Chiron	07-08-1999	—

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
SEA	A35	FARRAH ET AL., GenBank Accession Number AF186114, 01-13-2000.				
	A36	FERGUSON ET AL., Human Molecular Genetics 6:1589-1594, 1997				
	A37	FUJIWARA ET AL., GenBank Accession Number D79690, 02-09-1996.				
	A38	HILLIER ET AL., GenBank Accession Number AA166695, 11-09-1997.				
	A39	HILLIER ET AL., GenBank Accession Number AA682496, 12-19-1997.				
	A40	HILLIER ET AL., GenBank Accession Number R16882, 04-14-1995.				
	A41	HILLIER ET AL., GenBank Accession Number R16934, 04-14-1995.				
	A42	HILLIER ET AL., GenBank Accession Number T87299, 03-17-1995.				
	A43	MARRA ET AL., GenBank Accession Number AA422749, 10-16-1997.				
	A44	MARRA ET AL., GenBank Accession Number AI182472, 10-08-1998.				
	A45	MYERS, GenBank Accession Number G30081, 10-05-1996.				
	A46	NCI-CGAP, GenBank Accession Number AA906714, 06-09-1998.				
	A47	ZHANG ET AL., GenBank Accession Number AF134715, 03-28-2000.				

Sarada Prasad

10/30/01

Bridget E. Bunner 10/14/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? +

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many pages as necessary)			
		Application Number	09/589,285
		Filing Date	June 8, 2000
		First Named Inventor	YU et al.,
		Group Art Unit	1646 1647
		Examiner Name	Prasad, S. Brunner
Sheet	4	Attorney Docket Number	PF343P3C4

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Bob	A48	BAUMGARTH, Nicole, Secreted IgM versus BlyS in germinal center formation, Nature Immunology, (2000) 1:179.	
Bob	A49	CYSTER, JASON G., Marginal zone B cells may steal the limelight as the roles of Pyk-2 and BlyS begin to be elucidated. Pyk-2 deficiency leads to their loss whereas signaling via the BlyS receptor may augment their function, Nature Immunology, (2000) 1:9-10.	
Bob	A50	DO ET AL., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, J. Exp. Med., (2000) 192:953-964.	
Bob	A51	GROSS ET AL.; TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, (2000) 404:995-999.	
Bob	A52	HATZOGLOU ET AL., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.	
Bob	A53	HU ET AL., Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily, Genomics, 62:1023-107 (1999).	
Bob	A54	KANAKARAJ ET AL., BlyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-κ and Elk-1, Cytokine (2001) 13:25-31.	
Bob	A55	KHARE ET AL., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, PNAS, (2000) 97:3370-3375.	
Bob	A56	LAABI ET AL., Lymphocyte Survival--Ignorance is BlyS, Science Magazine, (2001) 289:883.	
Bob	A57	MACKAY ET AL., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, J. Exp. Med., (1999) 190:1697-1710.	
Bob	A58	MARSTERS, ET AL., Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI, Current Biology, (2000) 10:785-788.	
Bob	A59	MOORE ET AL., BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263.	
Bob	A60	NARDELLI ET AL., Synthesis and release of B-lymphocyte stimulator from myeloid cells, Immunobiology, (2001) 97:198-204.	
Bob	A61	PARRY ET AL., Pharmacokinetics and Immunological Effects of Exogenously administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice, The Journal of Pharmacology and Experimental Therapies, (2001) 296:396-404.	
Bob	A62	SCHNEIDER ET AL., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, J. Exp. Med., (1999) 189:1747-1756.	
Bob	A63	SHU ET AL., TALL-1 is a novel member of the TNF Family that is Down-regulated by Mitogens, J. Leukoc. Biol., 65:680-683 (1999).	

Bridget E. Brunner
Sarada Prasad

10/14/04

10/30/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? +

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)			
		Application Number	09/589,285
		Filing Date	June 8, 2000
		First Named Inventor	YU et al.,
		Group Art Unit	1646 11a47
		Examiner Name	Prasad, S. Bunner
Sheet	4	Attorney Docket Number	PF343P3C4

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
Bob	A64	THOMPSON ET AL., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, <i>J. Exp. Med.</i> , (2000) 192:129-135.	T ⁶
Bob	A65	WU ET AL., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BlyS, <i>The Journal of Biological Chemistry</i> (2000) 275:34578-34585.	
Bob	A66	XIA ET AL., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, <i>J. Exp. Med.</i> , (2000) 192:137-143.	
Bob	A67	YAN ET AL., Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity, <i>Nature Immunology</i> , (2000) 1:37-41.	
Bob	A68	YU ET AL., APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity, (2000) 1:252-256.	
Bob	A69	ZHANG ET AL., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, <i>The Journal of Immunology</i> , (2001) 166:6-10.	

Examiner	Sarada Prasad	Date Considered	10/30/01
----------	---------------	-----------------	----------

Bridget E. Bunner

10/14/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC, 20231.



Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					
Sheet	1	of	1	Attorney Docket Number	PF343P3C4

DO
NOT
PRINT

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
SCP	B1	09/912,293		ROSEN ET AL.	NOT PUBLISHED
	B2	08/971,317	A1	WILEY, S.R.	08/02/01

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		Office ³	Number ⁴			
SCP	B3	WO	98/18921	A1	Human Genome Sciences	5-07-1998
JL	B4	WO	00/50597	A2	Human Genome Sciences	8-31-2000

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

Examiner Signature	Sarada Prasad	Date Considered	8/14/02
--------------------	---------------	-----------------	---------

Bridget E. Brunner

10/4/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.